Health & Wellness 5 min read

Hengrui's Weekly Obesity Shot Cut Weight 16.4% at 4 mg and 17.7% at 6 mg in a Phase 3 Trial in China

A phase 3 trial in 567 adults in China found Hengrui's weekly injection ribupatide cut weight by up to 17.7%. We set out what each higher dose added, and what it cost in nausea.

Amelia Wong
Consumer Tech & Wellness Editor
Published 16 Nov 2026, 11:52 PM (SGT)
Share:
A grey bathroom scale with an analogue dial A grey bathroom scale with an analogue dial Photo by Joa70 on Pixabay
Advertisement

16 NOV 2026 — A once-weekly injection developed by Jiangsu Hengrui Pharmaceuticals cut body weight by 16.4% at a 4 mg dose and 17.7% at 6 mg over 48 weeks, against 1.4% on placebo, in a phase 3 trial of 567 adults in China published in JAMA on 15 November. The drug, ribupatide, acts on the same two gut-hormone receptors, GIP and GLP-1, as tirzepatide. A lower 2 mg dose cut weight by 10.7%.

The trial, GEMINI-1, enrolled adults without diabetes at 55 sites between May and June 2024 and followed them to 20 June 2025. To enter, people needed a body mass index of 28 or more, or 24 or more plus at least one weight-related condition, using China's cut-offs. The authors note the volunteers were relatively young, with a mean age of 34.4 years and a mean weight of 93.0 kg. Everyone, placebo group included, was given diet and exercise advice.

Hengrui sponsored the study, and the paper says the company took part in its design, data analysis and the decision to submit it. One of the two corresponding authors works for Hengrui. The other, Xiaoying Li, is at Zhongshan Hospital, Fudan University. The conflict-of-interest section reads "None reported." The trial is registered as NCT06396429, where the drug appears under its code name, HRS9531.

Each dose step, side by side

The paper reports each dose against placebo, not against the other doses. Set side by side, the figures show what the higher doses added. The numbers below come from the paper's abstract and Tables 2 and 3. The comparisons after the table are our arithmetic.

At week 482 mg4 mg6 mgPlacebo
Mean weight change−10.7%−16.4%−17.7%−1.4%
Lost at least 5%68.1%88.0%85.7%16.0%
Lost at least 15%30.2%52.8%63.8%7.1%
Lost at least 20%13.6%37.1%44.4%3.5%
Any gastrointestinal event47.9%58.2%63.1%23.1%
Nausea16.2%17.0%27.0%4.9%
Vomiting14.1%19.1%24.1%2.1%

Most of the gain arrived at the first step up. Moving from 2 mg to 4 mg added 5.7 points of average weight loss, while gastrointestinal events rose 10.3 points and nausea barely moved (16.2% to 17.0%). The second step bought much less. At 6 mg, average loss was 1.3 points higher than at 4 mg, and the placebo-adjusted confidence intervals for those two doses, 12.9 to 17.1 points and 14.2 to 18.4, overlap across most of their range. Nausea, meanwhile, rose 10 points to 27.0%.

The top dose did more at the far end. The share losing at least 15% of body weight rose 11 points, from 52.8% to 63.8%, and the share losing 20% or more rose 7.3 points. At the 5% threshold, 85.7% of the 6 mg group lost at least that much, slightly below the 88.0% on 4 mg. Among people who finished the 48 weeks, 85.8% of the 6 mg group were still on their target dose at the last injection, against 92.2% on 4 mg.

Safety findings and limits

Most stomach and gut effects were mild to moderate, the authors write, and occurred during dose escalation, which lasted up to 20 weeks. Only 0.7% of participants stopped treatment for adverse events, and nobody died. Three people on ribupatide developed gallbladder inflammation and three were diagnosed with papillary thyroid cancer, one of whom had previously been found to have thyroid nodules. In the investigators' assessment, the cancers were probably unrelated to the drug.

Advertisement

In a body-scan substudy of 67 participants with paired scans, median fat mass fell 26.1% on 4 mg and 34.9% on 6 mg, while lean mass fell 12.0% and 15.2%. Muscle strength was not measured.

The authors compare the result with earlier trials in Chinese or mostly East Asian adults, among them tirzepatide 15 mg (17.5% over 52 weeks, SURMOUNT-CN) and mazdutide 6 mg (14.0% over 48 weeks, GLORY-1). They caution that those comparisons are "only descriptive", because the trials differed in length, dosing schedules and statistical methods.

The authors are open about the trial's limits. Forty-eight weeks may have been too short to capture the full effect at 4 mg and 6 mg, since weight loss had not clearly levelled off in either group, and a cohort this young may say little about older patients. A cardiovascular outcomes trial in people with atherosclerotic cardiovascular disease is under way. On approval and price, the paper is silent.

Advertisement
Amelia Wong
Consumer Tech & Wellness Editor

Amelia Wong covers consumer technology, digital wellness, health-related tools, and practical lifestyle explainers for RECATOOLS.

View author profile → · Editorial policy

About this byline Amelia Wong is a RECATOOLS editorial persona for consumer technology and wellness-related tool coverage. Articles are produced and reviewed under RECATOOLS editorial supervision.

Corrections policy

Advertisement